The Vial site network continues to grow with the addition of Pediatric Skin Research LLC in Miami, FL. The clinic’s principal investigator is Dr. Mercedes E. Gonzalez, a dedicated pediatric dermatologist who has been practicing for over 11 years. Pediatric Skin Research LLC is Vial’s first pediatric dermatology clinic in the network and the first research clinic in Miami, FL.
The Vial partnership with Pediatric Skin Research will allow the clinic to expand their practice to further advance research and treatments in pediatric dermatology. The clinic runs trials for a wide range of indications including atopic dermatitis, dystrophic epidermolysis bullosa, plaque psoriasis, molluscum and warts.
Dr. Mercedes E. Gonzalez is a board-certified pediatric dermatologist who also serves as a clinical assistant professor at FIU Herbert Wertheim School of Medicine and at The Phillip Frost Department of Dermatology at the University of Miami Miller School of Medicine. Dr. Gonzalez graduated from Emory University and completed medical school at Rutgers-New Jersey Medical School. She was then accepted into the prestigious pediatrics program at the Morgan Stanley Children’s Hospital of New York–Columbia University where she solidified her interest in treating skin disorders. She then completed a dermatology residency at the top-ranked Ronald O. Perelman Department of Dermatology at New York University School of Medicine, followed by a clinical fellowship in pediatric dermatology. Dr. Gonzalez has published over 40 journal articles and has contributed to multiple dermatology textbooks. She is lead editor of Goodheart’s Photoguide to Common Pediatric and Adult Skin Diseases and Goodheart’s Same Site Differential Diagnosis.
On the partnership, Dr. Gonzalez said, “Our team at Pediatric Skin Research is dedicated to advancing treatments that will improve the lives of children with skin disease. We believe that this partnership with Vial will allow us to take the necessary next steps to continue that progress and allow us to grow our research capabilities exponentially.”
As Vial continues to expand into new therapeutic areas, the mission to run clinical trials with faster execution and higher quality to bring new therapies to market, remains at the forefront of their efforts.
